An observational study in Sarcoma, sponsored by University Hospital, Strasbourg, France. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Sarcomas with the EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript represent a new molecularly defined entity, first described in 2023 (1). There are 24 cases reported in the literature, including 3 descriptive series totaling 19 cases (1-3). Clinically, this is an aggressive entity affecting patients of varying ages (16-74 years), most commonly located in the sinonasal tract, and capable of involving both bone and soft tissue. A few extrasinonasal cases have also been reported. Histologically, two morphological groups have been described (3): the first group (the rarest) is characterized by a low-grade morphology with non-atypical spindle cells; the second group is morphologically high-grade, featuring spindle, round, or epithelioid cells and possible divergent differentiation (epithelial, neuroendocrine, striated muscle, or bone).
The immunophenotype of these lesions is nonspecific, with variable positivity for various markers such as S100, CD99, AE1/3, CD56, chromogranin, synaptophysin, SATB2, CD117, GFAP, and EMA.
Given the clinical, morphological, and immunohistochemical features of this entity, numerous differential diagnoses can be considered: synovial sarcoma, malignant tumor of the peripheral nerve sheaths, Ewing sarcoma, myoepithelial tumor, biphenotypic sinonasal sarcoma, etc.
1,609 studies on the registry are indexed under Sarcoma; 365 are open to participants now.
This study's planned enrollment of 10 is below the median of 120 across 218 observational studies indexed under Sarcoma.
Browse Sarcoma studies →University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
Counted across the registry records on this site, refreshed daily.
sarcomas
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Sarcomas exhibiting an EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript
Biological: methylation profiling
methylation profiling
Clustering Common to methylation analysis and RNA-seq.
Determine whether sarcomas with the EWSR1/FUS :: POU2AF3 fusion transcript constitute a distinct entity
Time frame: 11 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →